StockData
Fate Therapeutics Inc logo

Fate Therapeutics Inc (FATE) stock

FATENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/3021% below fair value
$1.05+0.03 (+2.94%)

Close on Nov 18, 2026Market cap $125.81MP/E –Yield –

Fate Therapeutics gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

No gross profit figures for Fate Therapeutics

Fate Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More Fate Therapeutics figures

See a number that looks wrong?